Swedencare AB (publ) SWDCF OTC · Healthcare · Sweden
$1.84 +0.00% +$0.00
Summary
50 / 100 · Bulios Score
What speaks for it
- Revenue grew by 14% a year over the last 3 years.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 17% a year over the last 3 years.
- It missed profit estimates 6 times in the last 8 quarters.
- Operating profit covers the interest on its debt only 2.0 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 34.8 SEK for 1 SEK of yearly profit. Over the last five years it was 99.0 SEK on average.
Valuation in detailIs it growing?
SlowlyRevenue (SEK)
Diluted EPS (SEK)
- Analyst estimate
Revenue grew by 62% a year over 5 years. Over the last 3 years it grew by 14% a year. Earnings per share fell by 17% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 SEK of revenue goes
- Cost of sales 54 SEK
- Sales and administration 39 SEK
- Taxes and other 4.0 SEK
- Net profit 3.1 SEK
Net profit, industry median (Medical - Pharmaceuticals) 6.1 SEK
Out of every 100 SEK of revenue, 3.1 SEK is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 8.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.65%
- Paid out of profit
- 58%
- Raised in a row
- 1 year
You receive $0.03 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $41 is 2,128% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.